Related Experiment Video
Updated: Dec 13, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Exploiting the full potential of proton therapy: An update on the specifics and innovations towards spatial or
L De Marzi1, A Patriarca2, N Scher2
1Institut Curie, centre de protonthérapie d'Orsay, campus universitaire, bâtiment 101, 91898 Orsay, France; Université PSL (Paris Sciences & Lettres), 60, rue Mazarine, 75006 Paris, France; Université Paris-Saclay, route de l'Orme-aux-Merisiers, RD 128, 91190 Saint-Aubin, France; Inserm U1021, centre universitaire, bâtiment 110, rue Henri-Becquerel, 91405 Orsay cedex, France; CNRS, UMR 3347, centre universitaire, bâtiment 110, rue Henri-Becquerel, 91405 Orsay cedex, France.
Abstract:
Prescription and delivery of protons are somewhat different compared to photons and may influence outcomes (tumour control and toxicity). These differences should be taken into account to fully exploit the clinical potential of proton therapy. Innovations in proton therapy treatment are also required to widen the therapeutic window and determine appropriate populations of patients that would benefit from new treatments. Therefore, strategies are now being developed to reduce side effects to critical normal tissues using alternative treatment configurations and new spatial or temporal-driven optimisation approaches. Indeed, spatiotemporal optimisation (based on flash, proton minibeam radiation therapy or hypofractionated delivery methods) has been gaining some attention in proton therapy as a mean of improving (biological and physical) dose distribution. In this short review, the main differences in planning and delivery between protons and photons, as well as some of the latest developments and methodological issues (in silico modelling) related to providing scientific evidence for these new techniques will be discussed.

